Browse BCL6

Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00651 BTB/POZ domain
Function

Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4(+) T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0000060 protein import into nucleus, translocation
GO:0001558 regulation of cell growth
GO:0001783 B cell apoptotic process
GO:0001818 negative regulation of cytokine production
GO:0001952 regulation of cell-matrix adhesion
GO:0001953 negative regulation of cell-matrix adhesion
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002250 adaptive immune response
GO:0002262 myeloid cell homeostasis
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002467 germinal center formation
GO:0002521 leukocyte differentiation
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002634 regulation of germinal center formation
GO:0002637 regulation of immunoglobulin production
GO:0002638 negative regulation of immunoglobulin production
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002701 negative regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002713 negative regulation of B cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002828 regulation of type 2 immune response
GO:0002829 negative regulation of type 2 immune response
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002890 negative regulation of immunoglobulin mediated immune response
GO:0002902 regulation of B cell apoptotic process
GO:0002903 negative regulation of B cell apoptotic process
GO:0006310 DNA recombination
GO:0006476 protein deacetylation
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007160 cell-matrix adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007219 Notch signaling pathway
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0007283 spermatogenesis
GO:0007568 aging
GO:0007569 cell aging
GO:0008593 regulation of Notch signaling pathway
GO:0010720 positive regulation of cell development
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0016049 cell growth
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0016570 histone modification
GO:0016575 histone deacetylation
GO:0017038 protein import
GO:0019724 B cell mediated immunity
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030183 B cell differentiation
GO:0030217 T cell differentiation
GO:0030218 erythrocyte differentiation
GO:0030308 negative regulation of cell growth
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031063 regulation of histone deacetylation
GO:0031065 positive regulation of histone deacetylation
GO:0031589 cell-substrate adhesion
GO:0032762 mast cell cytokine production
GO:0032763 regulation of mast cell cytokine production
GO:0032764 negative regulation of mast cell cytokine production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0034101 erythrocyte homeostasis
GO:0034504 protein localization to nucleus
GO:0035023 regulation of Rho protein signal transduction
GO:0035024 negative regulation of Rho protein signal transduction
GO:0035601 protein deacylation
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0042092 type 2 immune response
GO:0042093 T-helper cell differentiation
GO:0042100 B cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043371 negative regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043379 memory T cell differentiation
GO:0043380 regulation of memory T cell differentiation
GO:0044744 protein targeting to nucleus
GO:0045064 T-helper 2 cell differentiation
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0045580 regulation of T cell differentiation
GO:0045581 negative regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045620 negative regulation of lymphocyte differentiation
GO:0045622 regulation of T-helper cell differentiation
GO:0045623 negative regulation of T-helper cell differentiation
GO:0045628 regulation of T-helper 2 cell differentiation
GO:0045629 negative regulation of T-helper 2 cell differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0045746 negative regulation of Notch signaling pathway
GO:0045829 negative regulation of isotype switching
GO:0045910 negative regulation of DNA recombination
GO:0045926 negative regulation of growth
GO:0046578 regulation of Ras protein signal transduction
GO:0046580 negative regulation of Ras protein signal transduction
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046636 negative regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046639 negative regulation of alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0048232 male gamete generation
GO:0048289 isotype switching to IgE isotypes
GO:0048293 regulation of isotype switching to IgE isotypes
GO:0048294 negative regulation of isotype switching to IgE isotypes
GO:0048821 erythrocyte development
GO:0048872 homeostasis of number of cells
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050727 regulation of inflammatory response
GO:0050769 positive regulation of neurogenesis
GO:0050777 negative regulation of immune response
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050869 negative regulation of B cell activation
GO:0050871 positive regulation of B cell activation
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051058 negative regulation of small GTPase mediated signal transduction
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0051962 positive regulation of nervous system development
GO:0061082 myeloid leukocyte cytokine production
GO:0061515 myeloid cell development
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070229 negative regulation of lymphocyte apoptotic process
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0071887 leukocyte apoptotic process
GO:0090311 regulation of protein deacetylation
GO:0090312 positive regulation of protein deacetylation
GO:0090342 regulation of cell aging
GO:0090344 negative regulation of cell aging
GO:0090398 cellular senescence
GO:0098732 macromolecule deacylation
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902275 regulation of chromatin organization
GO:1902532 negative regulation of intracellular signal transduction
GO:1902593 single-organism nuclear import
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1905269 positive regulation of chromatin organization
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000515 negative regulation of CD4-positive, alpha-beta T cell activation
GO:2000772 regulation of cellular senescence
GO:2000773 negative regulation of cellular senescence
Molecular Function GO:0001161 intronic transcription regulatory region sequence-specific DNA binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0031490 chromatin DNA binding
GO:0043566 structure-specific DNA binding
GO:0044213 intronic transcription regulatory region DNA binding
Cellular Component GO:0005657 replication fork
> KEGG and Reactome Pathway
 
KEGG hsa04068 FoxO signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
R-HSA-5633008: TP53 Regulates Transcription of Cell Death Genes
R-HSA-6803205: TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BCL6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BCL6 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26928313Hepatocellular CarcinomaInhibit immunity (T cell function)TLR4-mediated BCL6 upregulation was crucial for PD-1(hi) B-cell induction by HCC environmental factors, and that effect was abolished by IL4-elicited STAT6 phosphorylation. Importantly, upon encountering PD-L1(+) cells or undergoing PD-1 triggering, PD-1(hi) B cells acquired regulatory functions that suppressed tumor-specific T-cell immunity and promoted cancer growth via IL10 signals.
26355571AIDS-Related Diffuse Large B-cell LymphomaPromote immunity (T cell function)When we examined the relationship between stromal immune cells and tumor molecular characteristics, stromal FOXP3+ Treg cells were found to be positively associated with tumor expression of p53 and cMYC, and inversely associated with BCL6.
27505670Diffuse Large B Cell LymphomaInhibit immunity; immunotherapy targetHerein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.
16880256Multiple myeloma(IgA, IgD, IgE, IgM, IgG)Inhibit immunityIn this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions.
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BCL6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BCL6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1990.511
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0620.971
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3970.728
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.260.633
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3620.882
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0520.749
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2780.486
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5560.702
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0310.985
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0060.996
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4870.813
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0660.436
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BCL6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BCL6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BCL6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BCL6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BCL6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BCL6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BCL6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBCL6
NameB-cell CLL/lymphoma 6
Aliases ZBTB27; LAZ3; BCL6A; ZNF51; zinc finger protein 51; BCL5A; B-cell lymphoma 5 protein; B-cell lymphoma 6 prot ......
Chromosomal Location3q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BCL6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.